A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19

Background and Objectives: Coronavirus disease 2019 (COVID-19) has caused global pandemics in the last 3 years, and the development of new therapeutics is urgently needed. This study aimed to assess the safety, tolerated, and prolonged retention of recombinant protein trefoil factor 2 (TFF2)- interf...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yan, Zhai, Guanxing, Fu, Weihui, Zhang, Xiaoyan, Xu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790930/
https://www.ncbi.nlm.nih.gov/pubmed/36578554
http://dx.doi.org/10.3389/fphar.2022.1063106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790930/
https://www.ncbi.nlm.nih.gov/pubmed/36578554
http://dx.doi.org/10.3389/fphar.2022.1063106

Ejemplares similares